New Publications

Amplification of CRKL Induces Transformation and Epidermal Growth Factor Receptor Inhibitor Resistance in Human Non-Small Cell Lung Cancers.
Read More / View Supplemental Materials
A genome-wide approach accounting for body mass index identifies genetic variants influencing fasting glycemic traits and insulin resistance.
Read More / View Supplemental Materials
Expression of the p53 Target CDIP Correlates with Sensitivity to TNFα-Induced Apoptosis in Cancer Cells.
Read More / View Supplemental Materials
Absolute quantification of somatic DNA alterations in human cancer.
Read More / View Supplemental Materials
RNA-SeQC: RNA-seq metrics for quality control and process optimization.
Read More / View Supplemental Materials

Scientific Publications

List
Filter

Found 7 results

Filters: Author is Gilliland, DG [Clear All Filters]

2009

Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1.Barbie, DA, Tamayo P., Boehm JS, Kim SY, Moody SE, Dunn IF, Schinzel AC, Sandy P., Meylan E., Scholl C., Fröhling S., Chan EM, Sos ML, Michel K., Mermel C., Silver SJ, Weir BA, Reiling JH, Sheng Q., Gupta PB, et al. Nature, 2009/11/05, Volume 462, Issue 7269, p.108-12, (2009) Read More / View Supplemental Materials

2008

Activating mutations in ALK provide a therapeutic target in neuroblastoma.George, RE, Sanda T., Hanna M., Fröhling S., Luther W 2nd, Zhang J., Ahn Y., Zhou W., London WB, McGrady P., Xue L., Zozulya S., Gregor VE, Webb TR, Gray NS, Gilliland DG, Diller L., Greulich H., Morris SW, Meyerson M., et al. Nature, 2008/10/16, Volume 455, Issue 7215, p.975-8, (2008) Read More / View Supplemental Materials

Id1 is a common downstream target of oncogenic tyrosine kinases in leukemic cells.Tam, WF, Gu TL, Chen J., Lee BH, Bullinger L., Fröhling S., Wang A., Monti S., Golub T. R., and Gilliland DG Blood, 2008/09/01, Volume 112, Issue 5, p.1981-92, (2008) Read More / View Supplemental Materials

2007

Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles.Fröhling, S., Scholl C., Levine RL, Loriaux M., Boggon TJ, Bernard OA, Berger R., Döhner H., Döhner K., Ebert BL, Teckie S., Golub T. R., Jiang J., Schittenhelm MM, Lee BH, Griffin JD, Stone RM, Heinrich MC, Deininger MW, Druker BJ, et al. Cancer cell, 2007/12/01, Volume 12, Issue 6, p.501-13, (2007) Read More / View Supplemental Materials

2006

Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9.Krivtsov, AV, Twomey D., Feng Z., Stubbs MC, Wang Y., Faber J., Levine JE, Wang J., Hahn WC, Gilliland DG, Golub T. R., and Armstrong SA Nature, 2006/08/17, Volume 442, Issue 7104, p.818-22, (2006) Read More / View Supplemental Materials

MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.Pikman, Y., Lee BH, Mercher T., McDowell E., Ebert BL, Gozo M., Cuker A., Wernig G., Moore S., Galinsky I., DeAngelo DJ, Clark JJ, Lee SJ, Golub T. R., Wadleigh M., Gilliland DG, and Levine RL PLoS medicine, 2006/07/01, Volume 3, Issue 7, p.e270, (2006) Read More / View Supplemental Materials

2005

Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.Levine, RL, Wadleigh M., Cools J., Ebert BL, Wernig G., Huntly BJ, Boggon TJ, Wlodarska I., Clark JJ, Moore S., Adelsperger J., Koo S., Lee JC, Gabriel S., Mercher T., D'Andrea A., Fröhling S., Döhner K., Marynen P., Vandenberghe P., et al. Cancer cell, 2005/04/01, Volume 7, Issue 4, p.387-97, (2005) Read More / View Supplemental Materials